| Biomarker ID | 385 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | TMPRSS2:ERG |
| Biomarker Basis | Expression Based (Fusion Based) |
| Biomolecule | mRNA |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | Fused in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR = 1.111 (95% CI: 0.592-1.874) |
| Effect on Pathways | Pathways Include(ERG):-Genes targeted by miRNAs in adipocytes WP1992,VEGFA-VEGFR2 Signaling Pathway WP3888 |
| Experiment | (Benign Samples + Gleason sums < 7) Vs ≥ 7 |
| Type of Biomarker | Prognostic |
| Cohort | 86 patients were taken into consideration for the test. Benign + Gleason sum < 7 (n = 60) vs Gleason sum >7 (n = 14) |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.773 (95% CI: 0.640- 0.906) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TMPRSS2, ERG |